PTHS · Pelthos Therapeutics Inc.
$27.50
-1.45 (-5.01%)
At close · Aug 14
Market Cap
$105.28M
Shares
3.83M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Francis Knuettel | CEO | $307,010 |
| Francis Knuettel II | Chief Executive Officer and Chief Financial Officer | $307,010 |
| Eric Lang | Chief Medical Officer | $287,502 |
| Christian Kopfli | Former Chief Executive Officer, Former Chief Strategy Officer, and Former Vice Chairman | $160,913 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Francis Knuettel II | Chief Financial Officer, Treasurer and Secretary | Terminated | 2026-05-21 |
| John M. Gay | treasurer and secretary | Appointed | 2026-04-10 |
| Francis Knuettel II | Chief Financial Officer | Terminated | 2026-04-10 |
| John M. Gay | Chief Financial Officer | Appointed | 2026-04-10 |
| Andrew J. Einhorn | member of the Board of Directors | Appointed | 2025-12-23 |
| Francis Knuettel II | Chief Executive Officer | Appointed | 2024-03-18 |
Key facts
CIK
1919246
CUSIP
171126204
13F (30d)
24 filings
24 filers
Visit website
Investor relations